CN110382465A - 亚磺酰基吡啶和其在癌症治疗中的用途 - Google Patents

亚磺酰基吡啶和其在癌症治疗中的用途 Download PDF

Info

Publication number
CN110382465A
CN110382465A CN201880010215.8A CN201880010215A CN110382465A CN 110382465 A CN110382465 A CN 110382465A CN 201880010215 A CN201880010215 A CN 201880010215A CN 110382465 A CN110382465 A CN 110382465A
Authority
CN
China
Prior art keywords
cancer
optionally
compound
independently
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880010215.8A
Other languages
English (en)
Chinese (zh)
Inventor
B·佩尔克曼
O·奥尔瓦尔
W·斯塔福德
K·安德松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obi Reek Treatment Co
Original Assignee
Obi Reek Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Reek Treatment Co filed Critical Obi Reek Treatment Co
Publication of CN110382465A publication Critical patent/CN110382465A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880010215.8A 2017-02-07 2018-02-07 亚磺酰基吡啶和其在癌症治疗中的用途 Pending CN110382465A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
US62/455,645 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN110382465A true CN110382465A (zh) 2019-10-25

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010215.8A Pending CN110382465A (zh) 2017-02-07 2018-02-07 亚磺酰基吡啶和其在癌症治疗中的用途

Country Status (12)

Country Link
US (2) US11208384B2 (enExample)
EP (1) EP3580204A1 (enExample)
JP (1) JP2020507624A (enExample)
KR (1) KR20190115011A (enExample)
CN (1) CN110382465A (enExample)
AU (1) AU2018218518B2 (enExample)
BR (1) BR112019016258A2 (enExample)
CA (1) CA3051644A1 (enExample)
MA (1) MA47450A (enExample)
MX (1) MX2019009356A (enExample)
RU (1) RU2019127896A (enExample)
WO (1) WO2018146468A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382464A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
BR112019016223A2 (pt) 2017-02-07 2020-04-07 Oblique Therapeutics Ab piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MX2019009356A (es) * 2017-02-07 2019-09-19 Oblique Therapeutics Ab Sulfinilpiridinas y su uso en el tratamiento del cancer.
EP3752151A1 (en) * 2018-02-12 2020-12-23 Cinda Pharma AB Thioredoxin reductase inhibitors for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064846D1 (en) 1979-12-19 1983-10-20 Duphar Int Res New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
WO1997008147A1 (de) 1995-08-24 1997-03-06 Basf Aktiengesellschaft N-heterocyclische verbindungen, zwischenprodukte für ihre herstellung, sie enthaltende mittel und ihre verwendung zur bekämpfung von schadpilzen
WO1998054139A1 (de) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2019827A1 (en) 2006-04-28 2009-02-04 Avexa Limited Integrase inhibitors 3
US20090005422A1 (en) * 2006-05-22 2009-01-01 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
US9421211B2 (en) 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
CN108752280A (zh) 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
EP2535059A4 (en) 2010-02-10 2014-03-12 Public Univ Corp Yokohama City USE OF A MSIN3B BINDING COMPOUND FOR SPECIFIC BINDING TO THE NEURONIC RESTRICTIVE SILENCER FACTOR (NRSF)
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
AU2013216885B2 (en) 2012-02-10 2017-08-03 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACs)
JP6393322B2 (ja) 2013-07-10 2018-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
MX2019009356A (es) * 2017-02-07 2019-09-19 Oblique Therapeutics Ab Sulfinilpiridinas y su uso en el tratamiento del cancer.
BR112019016223A2 (pt) 2017-02-07 2020-04-07 Oblique Therapeutics Ab piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
KR20190115014A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 하이드로카르빌설포닐-치환된 피리딘 및 암의 치료에서 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382464A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途

Also Published As

Publication number Publication date
CA3051644A1 (en) 2018-08-16
MX2019009356A (es) 2019-09-19
AU2018218518B2 (en) 2022-03-17
US11208384B2 (en) 2021-12-28
JP2020507624A (ja) 2020-03-12
BR112019016258A2 (pt) 2020-04-07
US20220177430A1 (en) 2022-06-09
KR20190115011A (ko) 2019-10-10
RU2019127896A3 (enExample) 2021-05-18
AU2018218518A1 (en) 2019-08-15
RU2019127896A (ru) 2021-03-09
MA47450A (fr) 2019-12-18
WO2018146468A1 (en) 2018-08-16
US20200024233A1 (en) 2020-01-23
EP3580204A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
CN110382465A (zh) 亚磺酰基吡啶和其在癌症治疗中的用途
US11168069B2 (en) Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN113121574B (zh) 嘌呤衍生物及其在医药上的用途
JP6636153B2 (ja) ピリジン及び癌治療におけるそれらの使用
JP7229176B2 (ja) ヒドロカルビルスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
CN110382486A (zh) 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途
US20200113897A1 (en) Pyridazinones and their use in the treatment of cancer
CA2995075C (en) Tricyclic compounds and their use in the treatment of cancer
CN118084844A (zh) 一种PI3Kα抑制剂及其在医药上的应用
WO2019184919A1 (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
RU2777596C2 (ru) Гетероциклилсульфонил-замещенные пиридины и их применение при лечении рака
RU2772935C2 (ru) Гетероарилсульфонил-замещенные пиридины и их применение при лечении рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191025

WD01 Invention patent application deemed withdrawn after publication